Fate Therapeutics treats first SLE patient with FT819; advances autoimmune pipeline

FATE THERAPEUTICS INC

First SLE patient dosed in Phase 1 autoimmunity study of FT819 (CD19 CAR T); discharged after 3 days with no notable AEs.
FT819 translational data: rapid deep B-cell depletion, tissue trafficking, plasma cell depletion; fludarabine not required in some cases.
FT522 (CAR NK) initial observations: rapid sustained B-cell depletion and enhanced persistence vs FT596 in first two BCL patients.
Company completed dose escalation in FT819 BCM study; will focus FT819 solely on autoimmunity; FT522 IND for autoimmune diseases expected mid-2024.
FT819 safety in BCM study: no DLTs, ICANS, or GvHD; low-grade CRS in 14% of patients; no study discontinuations or deaths.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.